Emerging empirical evidence on the ethics of schizophrenia research.
Many challenging ethical questions come with the scientific efforts to understand the nature and treatment of schizophrenia. The empirical study of ethical aspects of schizophrenia research has sought to clarify and resolve many of these questions. In this article we provide an overview of the existing data-based literature on schizophrenia research ethics and outline directions for future inquiry. We examine 5 broad categories of inquiry into the ethics of schizophrenia research: (1) Scientific designs (eg, placebo-controlled studies and medication-free intervals, prodromal and high-risk research, and genetics research); (2) informed consent and decision-making capacity, including assessment of decisional abilities, as well as intervention studies; (3) understanding and perceptions of risk and benefit (including the therapeutic misconception); (4) influences on research participation (including voluntarism, altruism, and other motivations); and (5) key participant safeguards, such as protocol review and participant advocates. We discuss how empirical work in each of these areas answers certain questions and raises new ones. Finally, we highlight important gaps in our understanding of ethically relevant aspects of schizophrenia research and offer a specific research agenda for empirical ethics.
Dunn
Laura B
LB
Department of Psychiatry, University of California, San Diego, USA. Ldunn@ucsd.edu
Candilis
Philip J
PJ
Roberts
Laura Weiss
LW
D035843:Biomedical Research / Q000941:ethics*; D003657:Decision Making; D019348:Empiricism; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence; D008605:Mental Health Services / Q000941:ethics / Q000331:legislation & jurisprudence; D012559:Schizophrenia / Q000628:therapy*; D014481:United States